Advertisement
Advertisement
U.S. Markets open in 9 hrs 24 mins
Advertisement
Advertisement
Advertisement
Advertisement

Kezar Life Sciences, Inc. (KZR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
7.31+0.41 (+5.94%)
At close: 04:00PM EST
7.31 0.00 (0.00%)
After hours: 05:11PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close6.90
Open6.94
Bid7.17 x 1100
Ask8.60 x 800
Day's Range6.93 - 7.32
52 Week Range4.31 - 18.55
Volume545,176
Avg. Volume662,960
Market Cap388.877M
Beta (5Y Monthly)0.26
PE Ratio (TTM)N/A
EPS (TTM)-0.95
Earnings DateMar 15, 2023 - Mar 20, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est18.75
  • Business Wire

    Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    SOUTH SAN FRANCISCO, Calif., January 13, 2023--Kezar Life Sciences, Inc., (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the Compensation Committee of the company’s Board of Directors granted two employees nonqualified stock options to purchase 65,000 shares of its common stock with an exercise price of $6.84 per share, which is equal to the closing price of Kezar’s common

  • Business Wire

    Kezar Life Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., January 04, 2023--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that John Fowler, Co-founder and Chief Executive Officer, will present a corporate overview at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 2:15 pm PT in San Francisco, CA.

  • Business Wire

    Kezar Life Sciences Presents Positive Complete Results from the MISSION Phase 2 Trial Evaluating Zetomipzomib in Lupus Nephritis at the American College of Rheumatology Convergence 2022

    SOUTH SAN FRANCISCO, Calif., November 14, 2022--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that it presented the complete data set from the MISSION Phase 2 clinical trial evaluating zetomipzomib in active lupus nephritis (LN) at the American College of Rheumatology (ACR) Convergence 2022 in Philadelphia, PA.

Advertisement
Advertisement